Parkinson’s linked to gene on Y-chromosome in men for the first time

By Hudson Institute communications. Reviewed by Dr Joohyung Lee

Dr Joohyung Lee
Dr Joohyung Lee

A gene on the male Y-chromosome has been found to make males more susceptible to Parkinson’s disease (PD). The discovery may open up new ways to target and treat the progression of this debilitating disease in men.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily associated with an inability to initiate and control voluntary movement.

Professor Vincent Harley discussing Parkinson’s Disease (PD)

The onset of Parkinson’s disease is caused by a loss of dopamine neurons in the midbrain. While it is unknown what causes this neuron loss, being male has always been linked as one of the strongest risk factors to developing the disease.

Men are twice as likely to develop PD as women and the progression of the disease is more rapid in men. Traditionally, sex differences in PD have been attributed to the protective actions of estrogen in females.

However, the finding of this pre-clinical study by Dr Joohyung Lee and Professor Vincent Harley, published in the prestigious Proceedings of the Natural Academy of Sciences, show for the first time that a gene called SRY on the male Y chromosome exacerbates risk factors as well as disease progression in males.

Remarkably, the researchers found that when they lowered the expression of the SRY gene by using synthetic gene therapy, they found reduced dopamine neuron loss and diminished motor symptoms in males.

Their study is a world first in identifying a male-specific therapeutic target for a neurological disease.

Prof Harley said, “Currently, PD therapies only treat symptoms and do not halt or slow the disease.

“Male and female brains are different at all levels: molecular, cellular and behavioural. That’s why we believed it was important to explore potential sex genetic related causes of the disease,” he said.

Study findings

In adult males, the SRY gene controls how the brain functions. SRY proteins regulate the synthesis of dopamine which controls voluntary movement.

The research team led by Dr Lee and Prof Harley found that males with PD produced an abnormally high amount of the SRY protein in their mid-brain.

Dr Lee said, “In the healthy adult male brain, the SRY gene functions to control dopamine neurons and dopamine synthesis. However, we think that in cases of PD, when the male brain starts losing dopamine neurons, the SRY gene tries to compensate by producing more dopamine.

“This over production of dopamine exacerbates inflammation in the male brain,” he said.

The findings suggest that supressing the SRY gene with therapy represents a new sex-specific strategy to slow or prevent dopamine loss for men affected with PD, which would slow down PD progression in men.

SRY gene facts

  • At the embryonic stage, the SRY gene initiates male-sex determination by directing the development of the gonads to testes, rather than ovaries.
  • In adult human males, the SRY gene is also expressed in non-reproductive tissues, such as the heart, adrenal glands, kidneys and brain.
  • SRY regulates the creation of dopamine neurons which controls voluntary movement.

Next steps

Dr Lee said, “This is a very exciting step towards minimising PD in males,” he said.

Prof Harley said, “We hope our study excites interest in developing SRY-based inhibitors for men with PD.”

Collaborators | University of California, Los Angeles

This research was supported by | Victorian Government’s Operational Infrastructure, Support Program, Australian NHMRC, CASS foundation, Rebecca L. Cooper Foundation, Helen McPherson Smith Trust and National Institute of Health (NIH) USA.

In this article

About Hudson Institute

Hudson Institute’ s research programs deliver in five areas of medical need – inflammation, cancer, reproductive health, newborn health, and hormones and health. More

Hudson News

Get the inside view on discoveries and patient stories

“Thank you Hudson Institute researchers. Your work brings such hope to all women with ovarian cancer knowing that potentially women in the future won't have to go through what we have!”

Alana Chantry